These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1164 related items for PubMed ID: 17044040

  • 1. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 2. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
    Koochekpour S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, Grabowski GA, Culig Z, Minokadeh A.
    J Cell Biochem; 2007 Jun 01; 101(3):631-41. PubMed ID: 17171640
    [Abstract] [Full Text] [Related]

  • 3. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 4. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
    Koochekpour S, Lee TJ, Sun Y, Hu S, Grabowski GA, Liu Z, Garay J.
    J Cell Biochem; 2008 Aug 15; 104(6):2272-85. PubMed ID: 18481277
    [Abstract] [Full Text] [Related]

  • 5. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 7. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG, Liu XM, Kreis W, Budman DR.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909
    [Abstract] [Full Text] [Related]

  • 8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 27; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 9. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 11. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M, Diamandis EP.
    Biol Chem; 2008 Jun 01; 389(6):773-80. PubMed ID: 18627304
    [Abstract] [Full Text] [Related]

  • 12. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 13. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 14. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 16. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 17. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 18. Associations of saposin C, Src, and androgen receptor upregulate the expression and function of androgen receptor in human prostate cancer cells.
    Ding Y, Wang X, Xu A, Xu X, Tian K, Young CY, Yuan H.
    J Cell Biochem; 2011 Mar 01; 112(3):818-28. PubMed ID: 21328455
    [Abstract] [Full Text] [Related]

  • 19. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 01; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.